Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SCD CRISPR/Cas9 KO Plasmid (h): sc-401516
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SCD CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SCD genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SCD Antibody (D-5): sc-515875
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SCD CRISPR/Cas9 KO Plasmid (h) | sc-401516 | 20 µg | $397.00 |
Overview
Stearoyl-CoA desaturase (SCD) is an endoplasmic reticulum membrane enzyme that introduces a cis double bond into saturated fatty acyl-CoAs, generating monounsaturated fatty acids such as oleate and palmitoleate. By controlling the saturated-to-monounsaturated lipid ratio, SCD influences membrane fluidity, lipid droplet biogenesis, and the synthesis of triglycerides, cholesterol esters, and phospholipids. SCD activity integrates with central metabolic programs including SREBP-dependent lipogenesis, AMPK-linked energy sensing, and ER stress responses. Dysregulated SCD expression and desaturation capacity have been associated with altered metabolic homeostasis and lipid remodeling observed in contexts such as insulin resistance, steatosis, and tumor cell adaptation to nutrient stress.
SCD CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SCD gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SCD together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SCD open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SCD protein expression.
This CRISPR knockout system enables efficient generation of SCD-deficient cell models for investigation of SCD signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SCD exon(s) critical for SCD function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SCD genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SCD CRISPR/Cas9 KO Plasmid (h) and SCD CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SCD locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SCD HDR Plasmid (h) and SCD HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SCD homology arms to support homology-directed repair at defined SCD target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.